ArticleTrials2026
Efficacy, safety, and cost-effectiveness of Sophora flavescens films in the treatment of postpartum vaginal dysbiosis in women (SFF-PVD Study): study protocol for a multicenter double-blind randomized controlled trial.
Article in Trials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundThe vaginal microecological barrier in postpartum women is particularly vulnerable, and its stability plays a crucial role in maintaining reproductive tract health. Emerging evidence indicates that Sophora flavescens films (SFF) may have therapeutic potential in managing postpartum vaginal dysbiosis (PVD). This study is therefore designed to evaluate the safety, efficacy, and cost-effectiveness of SFF in the treatment of PVD. METHODS AND ANALYSIS: This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. A total of 292 participants diagnosed with PVD will be enrolled from four tertiary hospitals across China. Eligible participants will be randomly assigned to receive either SFF or a placebo, administered intravaginally once daily for seven consecutive days (each film contains 100 mg of oxymatrine). The primary outcome is the therapeutic efficacy of SFF in improving PVD. Secondary outcomes include changes in vaginal health scores, vaginal inflammation scores, quality of life, levels of vaginal inflammatory biomarkers, incidence of adverse events, and treatment-related costs. Multivariable logistic regression models and analysis of covariance (ANCOVA) will be employed for analysis. Furthermore, a cost-effectiveness analysis (CEA) from the patient's perspective will be performed using a decision tree model to evaluate the pharmacoeconomic profile of SFF. DISCUSSION: This study provides evidence-based insights into clinical interventions for PVD. It uses standardized assessment criteria and a double-blind design. However, the findings may be influenced by subjective judgment and regional limitations. Future multicenter studies are needed. They will validate therapeutic efficacy. This will help optimize clinical decision-making and economic evaluations.
trial registrationThe study is registered at http://www.chictr.org.cn (ChiCTR2500102388, 14 May 2025).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.